Tinzaparin sodium

Drug Profile

Tinzaparin sodium

Alternative Names: Innohep; Logiparin

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma; Novo Nordisk
  • Developer LEO Pharma
  • Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis

Most Recent Events

  • 09 May 2017 LEO Pharma completes a phase II trial in Thrombosis in France (SC) (NCT02260414)
  • 07 Oct 2016 Additional efficacy data from the phase III CATCH trial in Thrombosis presented at the 41st European Society for Medical oncology Congress (ESMO-2016)
  • 01 May 2014 LEO Pharma completes a long-term phase III global trial in Thrombosis (Prevention of recurrence of venous thromboembolism in cancer patients) (NCT01130025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top